Welcome to visit Clinical Medication Journal!

26 November 2021, Volume 19 Issue 11
    

  • Select all
    |
    Review
  • Research progress on lipid emulsion in neonatal parenteral nutrition
    WU Jie, WANG Xin
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 1-5. https://doi.org/10.3969/j.issn.1672-3384.2021.11.001
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Parenteral nutrition （PN） has been widely used in preterm infants and it is a relatively safe method to prevent nutritional deficiencies. European Pediatric Gastroenterology， Hepatology and Nutrition Association， European Society for Parenteral and Enteral Nutrition， European Society for Pediatric Research and Chinese Society for Parenteral and Enteral Nutrition all pointed out in the latest guidelines on PN for children that intravenous lipid emulsion（IVLE） is an indispensable part of neonatal PN. This article reviewed the development of IVLE and research trials of preterm infants using nutritional support in recent years to investigate the use of various lipid emulsions in PN， and to evaluate the different lipid emulsions may have different effects on the clinical outcomes of neonatal patients.
    • Drug in the Future
  • A new drug for KRAS G12C mutant non-small cell lung cancer—Adagrasib
    ZHOU Lin, CHENG Mao-sheng, LIU Yang
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 6-9. https://doi.org/10.3969/j.issn.1672-3384.2021.11.002
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    • Lastest Drug
  • The first anti-CD19 antibody-drug conjugate for the treatment of large B cell lymphoma—Loncastuximab Tesirine-lpyl
    LIU Yue, ZHANG Hai-ying
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 10-14. https://doi.org/10.3969/j.issn.1672-3384.2021.11.003
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    • Original Article
  • In vitro antimicrobial activity of Ceftazidime/Avibactam and other 13 antibiotics against Pseudomonas aeruginosa in different specimens of elderly patients
    GAO Ming, AI Xiao-man, HU Yun-jian
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 15-19. https://doi.org/10.3969/j.issn.1672-3384.2021.11.004
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective This study was to compare the in vitro antimicrobial activity of Ceftazidime/Avibactam （CZA） and other 13 antibiotics against Pseudomonas aeruginosa （PA） isolated from different specimens of elderly patients， so as to provide a new treatment idea in clinical practice. Methods Collected ninety consecutive strains of PA from Beijing Hospital's elderly patients during the period from January 1 to June 30， 2020. Kirby-bauer method was used to test the susceptibility of CZA and other 13 antibiotics.WHONET 5.6 and SPSS 19.0 software were used to analyze and process the data. Result Of the isolates tested， the sensitivity rate of CZA against PA reached 94.4%，better than that of Ceftazidime（68.9%） and Meropenem（54.4%）（P<0.01）. For carbapenem-nonsusceptible PA and carbapenem-susceptible PA， the sensitivity rates of CZA were 89.8% and 100.0%（P=0.10）， respectively. The sensitivity rate of CZA reached over 85.0% among different age groups. Conclusion CZA has a good sensitivity to PA in elderly patients，and it has a sensitivity advantage compared with other beta lactamase drugs.Therefore，it is a potential treatment for PA infection.
  • Conscious sedation efficacy of Dexmedetomidine at different doses combined with Remifentanil during transrectal prostatic biopsy
    HOU Chun-yan, HU Li-ping, TIAN Guo-gang, TIAN Yi
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 20-24. https://doi.org/10.3969/j.issn.1672-3384.2021.11.005
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective Conscious sedation efficacy of Dexmedetomidine at different doses combined with Remifentanil was observed during transrectal ultrasound-guided prostatic biopsy. Methods Ninety patients scheduled for transrectal ultrasound-guided prostatic biopsy were randomly divided into three groups， i.e. medium-dose Dexmedetomidine group （0.5 μg/kg， group D1）， low-dose Dexmedetomidine group （0.3 μg/kg， group D2） and another low-dose Dexmedetomidine group （0.2 μg/kg， group D3），there were 30 cases in each group. Dexmedetomidine was given 15 mins before surgery over 10 mins respectively in each group and Remifentanil was given 10 mins before surgery at the speed of 0.1 μg·kg-1·min-1 until the surgery finished. The following outcomes were observed and recorded， including operation time， perfect analgesic ratio， heart rate （HR）， mean artery blood pressure （MAP）， oxyhemoglobin saturation （SpO2）， Ramsay sedation score before anesthesia （T0）， 15 mins after drug administration （T1）， when inserting the ultrasonic probe （T2）， when breaking through the prostate capsule （T3） and 5 mins after the operation （T4） as well as adverse reactions such as body movement， respiratory depression， bradycardia， hypotension and postoperative delirium. Results MAP and HR at T1-T4 in group D1 were lower than those at T0 （P<0.05）. MAP and HR at T1 in group D2 and group D3 were lower than those at T0 （P<0.05）. MAP and HR at T2 and T4 in group D1 were lower than those in group D3 （P<0.05）. Ramsay sedation score at T1-T4 in group D1 were higher than those at T0 （P<0.05）， and ramsay sedation score at T1-T2 in group D1 were higher than those in group D3 （P<0.05）. The incidences of respiratory depression and body movements in group D3 was higher than those in group D1 and group D2 （P<0.05）. The perfect analgesic ratio in group D3 was lower than those in group D1 and group D2 （P<0.05）. The incidences of bradycardia and hypotension in group D1 was higher than those in group D3 （P<0.05）. There were no significant differences in the incidences of nausea and vomiting and postoperative delirium among three groups （P>0.05）. Conclusion 0.3 μg/kg Dexmedetomidine combined with 0.1 μg·kg-1·min-1 of Remifentanil continuous intravenous infusion could offer safety and efficient conscious sedation and analgesia for transrectal ultrasound guided prostatic biopsy.
  • The application value of Tamsulosin after extracorporeal shock wave lithotripsy and its effect on the level of inflammatory factors
    FAN Xue-yong, LIU Quan
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 25-29. https://doi.org/10.3969/j.issn.1672-3384.2021.11.006
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective This study was designed to investigate the application value of Tamsulosin in patients with extracorporeal shock wave lithotripsy （ESWL） and its effect on the level of inflammatory factors. Methods A total of 100 patients with ureteral calculi complicated with renal colic were selected from November 2019 to November 2020 in Chaoyang Central Hospital. The patients were divided into the control group and the observation group by random number table method with 50 cases in each group. After ESWL， the control group was immediately treated with Nifedipine， while the observation group was immediately treated with Tamsulosin. At the end of treatment， the clinical efficacy， calculi discharge time， hospital saty， hospital costs， postoperative pain and safety of 2 groups were compared， and the changes of interleukin 6 （IL-6）， interleukin 10 （IL-10） and C reactive protein （CRP） before and after treatment were recorded. Results The total effective rate of observation group was 92.00%， significantly higher than that of control group （76.00%） with statistically significant difference （P<0.05）. The calculi discharge time and hospital stay in the observation group were （5.12±0.78） d and （8.56±1.31） d， both shorter than those in the control group ［（6.71±0.89） d and （9.77±1.24） d］， and the differences were statistically significant （P<0.05）. The incidence of renal colic was 6.00%， the utilization rate of analgesics was 8.00%， and the visual analogue scale/score （VAS） score was （1.78±0.31） points. Compared with the control group ［20.00%，30.00%，（2.57±0.53） points）］， the difference was statistically significant （P<0.05）. After treatment， Il-6， IL-10 and CRP increased in both groups， and the levels in the observation group was lower than those in the control group with statistically significant difference （P<0.05）. Electrocardiogram， liver and kidney function and hematuria routine were monitored during medication， and no obvious abnormalities were found. Conclusion Tamsulosin has a significant clinical effect after extracorporeal shock wave lithotripsis， which can shorten the time of stone exhaustion， relieve body injury， relieve postoperative pain， relieve inflammatory reaction and improve prognosis. It is worthy of clinical application.
  • The efficacy and safety of different doses of Sorafenib in the treatment of hepatocellular carcinoma： a comparison study
    LU Yu-ting, LIU Hui, SHEN Yan-jun, ZHAN Han-qiu
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 30-33. https://doi.org/10.3969/j.issn.1672-3384.2021.11.007
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective To retrospectively analyze the efficacy and safety of 800 mg/d standard dose and 400 mg/d low-dose Sorafenib in the treatment of hepatocellular carcinoma （HCC）. Methods The patients with HCC treated with Sorafenib in Beijing DiTan Hospital from 2018-9-1 to 2020-11-1 were included in the analysis， including 48 cases in the standard dose group and 22 cases in the low-dose group. The objective response rate （ORR）， the disease control rate （DCR）， the time to progression （TTP） and safety of the two groups were evaluated. Results After 1， 3， 6 and 12 months， the DCR of standard dose group and the low-dose group was 86.5% vs. 90.0%， 82.9% vs. 61.9%， 68.2% vs. 60.0%， 50.0% vs. 33.3%，respectively；and ORR was 32.4% vs. 35.0%， 31.7% vs. 19.0%， 22.7% vs. 20.0%， 12.5% vs 0，there was no significant difference in ORR and DCR between the two groups （all P>0.05）. The main adverse reactions in the standard dose group and the low-dose group were including increased blood pressure， diarrhea， fatigue， and hand-foot syndrome. There was no statistical difference in the incidence of these adverse reactions between the two groups （P>0.05）. Conclusion Compared with the standard dose， the efficacy and safety of low-dose Sorafenib in the treatment of HCC are basically the same.
  • Quality comparison of Epirubicin Hydrochloride for Injection from different manufacturers
    SONG Yu, DU Li-ping, CAO Ya-rui, ZHANG Yan, MEI Dan
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 34-40. https://doi.org/10.3969/j.issn.1672-3384.2021.11.008
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective To compare the quality of Epirubicin Hydrochloride Injection from different manufacturers based on the current clinical use， so as to provide reference for clinical use and standard improvement. Methods By referring to the pharmacopoeia of various countries， the standards issued by the related ministry of health， the standards issued by the bureau and relevant literature， the clinically meaningful indexes were selected for comparison， including the appearance of the preparation， pH value， resolution time， relevant substances， content and the stability of the sample in different solvent and different storage conditions， etc. The quality differences of Epirubicin Hydrochloride preparation from 3 manufacturers in the market were compared. Results A total of 9 batches of samples from 3 manufacturers were all orange-red loose lumps. In the comparison of instructions， the storage conditions of B and C manufacturers were stricter than those of A manufacturers， and the temperature requirements were increased. As per the resolution time， both manufacturers A and C was less than 60 s， which met the enterprise standard of A， while the average resolution time of manufacturer B was more than 2 min， and the enterprise standard of manufacturer B did not stipulate the resolution time. In terms of the percentage content and related substances of each batch of samples from the three manufacturers prepared into solutions in different solvents， the amount of doxorubicin in the products of manufacturer A was about two times as the manufacturer B， while only a few samples of manufacturer C were detected in the first batch. Conclusion Different manufacturers of Epirubicin Hydrochloride for Injection have certain differences in the re dissolution time， stability， content and related substances. The redissolution time of related substances doxorubicin， doxorubicin ketone and powder injection are quite different. It was suggested that the manufacturers should continue to improve the quality of the preparation from the aspects of raw and auxiliary materials and preparation technology.
  • Efficacy of different endocrine therapy for patients with hormone-sensitive advanced breast cancer： a network Meta-analysis
    YAO Juan, FU Ya-fu
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 41-46. https://doi.org/10.3969/j.issn.1672-3384.2021.11.009
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective This study was designed to investigate the efficacy of different endocrine therapy methods in patients with hormone receptor （HR） positive advanced breast cancer. Methods From January 1， 2000 to December 31， 2019， PubMed， Web of Science， Embase and CNKI databases were used to search for randomized controlled studies according to the inclusion criteria， and then the data in the literature were extracted. The network Meta-analysis was performed using Stata 14.0 software， and P-score of the Haas ranking method was used to compare the advantages of different treatment regimens， and the differences in progression-free survival （PFS） and overall survival（OS） were evaluated. Results A total of 20 english literatures were included in the study. Seven of them used endocrine therapy with a combination of targeted drugs which the combined effect （hazard ratio， HR） of PFS showed that HR was 0.64 （95%CI：0.54-0.76）. The group without targeted drug treatment had HR=0.86 （95%CI：0.75-0.98）， and the combined analysis on the OS of the combined and non-combined targeted drug treatment group showed that HR=0.92 （95%CI： 0.84-1.01）. Combined with the adverse events （AE） and treatment response （TR）， the results showed that the combination of the targeted drug Palbociclib and Letrozole was the best （P-score=0.99）， followed by Buparlisib plus Fulvestrant （P-score=0.73） and single use of Letrozole （P-score=0.60）. Conclusion Combining AEs and TR as co-factors for screening optimal treatment， we recommend clinically that patients with HR positive breast cancer， endocrine therapy， combined with targeted drugs can help improve PFS in patients with HR positive breast cancer.
  • Mini health technology assessment of Evolocumab and Alirocumab
    WU Hui-zhen, QIU Xue-jia, CAO Ge-xi
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 47-53. https://doi.org/10.3969/j.issn.1672-3384.2021.11.010
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective To conduct mini health technology assessment （Mini HTA） on PCSK9 inhibitors Evdocumab and Alirocumab， so as to provide basis for drug selection and rational use of Evolocumab and Alirocumab in medical institutions． Methods According to The Quick Guide for Drug Evaluation and Eelection in Chinese Medical Institutions， Mini HTA of Evolocumab and Alirocumab was carried out in terms of pharmaceutical characteristics， effectiveness， safety， economy and other attributes by consulting literature， guidelines， instructions，drug trading and procurement platform， essential drugs and medical insurance catalogue. Results The final scores of Evolocumab and Alirocumab were 80.3 and 73.5， respectively. Compared with Evolocumab， Alirocumab has a shorter time on the market and less clinical experience. Evolocumab could be administered once every 2 weeks or once a month； Alirocumab should be administered only once every 2 weeks. Evolocumab was superior to Alirocumab in safety and economy. Conclution Evolocumab and Alirocumab are strong recommendations for drug selection in medical institutions.
  • Data mining and analysis of adverse event risk signals of Belimumab
    TAN Ling, LI Xin-gang
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 54-60. https://doi.org/10.3969/j.issn.1672-3384.2021.11.011
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective To explore the risk signals of adverse events related to Belimumab and its safety in clinical application. Methods The reported odds ratio （ROR） method was used to mine the risk signals related to Belimumab in US Food and Drug Administration （FDA） adverse event reporting system from March 9， 2011 to August 4， 2021. The adverse event of top 50 reports and signal strength were calculated and analyzed. Results There were totally 13 785 reports of adverse events related to belimumab （13 785/11 524 326， 0.12%）， Except gender unknown （7.83%）， more female patients than male （86.42% vs. 5.75%）， and Except age unkown （5026%）， more adult patients （18-64 years old） than elderly （≥65 years old） （44.99% vs.3.82%）. The top 50 reported adverse events mainly included general disorders and administration site conditions（15）， infections and infestations （7）， musculoskeletal and connective tissue disorders （5）， etc. The top 50 signal strength adverse events mainly involved infections and infestations （16）， respiratory， thoracic and mediastinal disorders （5）， general disorders and administration site conditions （5）， et al. A total of 43 adverse events were not covered by the instructions， which mainly related to infections and infestations （11）， such as herpes zoster cutaneous disseminated（ROR=41.47，95% CI： 19.41-88.61）， herpes zoster meningitis （ROR=29.13，95% CI： 9.21-92.13）， skin bacterial infection（ROR=6.88，95% CI：2.21-21.44）， etc. Conclusion In addition to the adverse event mentioned in the instructions. It is necessary to pay close attention to infection test results and symptoms， skin conditions and blood coagulation test results， and identify adverse events as soon as possible， so as to ensure the safe medication of patients.
  • Influence of pre-prescription review based on drug use evaluation criteria on the rationality of clinical application of Ketorolac Tromethamine
    SONG Jia-wei, WANG Yuan-yuan, CHEN Hui-juan, WANG Long, ZHANG Fang-fang, LIU Li, WU Wei
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 61-64. https://doi.org/10.3969/j.issn.1672-3384.2021.11.012
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective This study was designed to explore the influence of custom rules of pre-prescription review on the rationality of clinical application of Ketorolac Tromethamine. Methods According to the established drug use evaluation （DUE） criteria of Ketorolac Tromethamine， the prescription pre-review rules were customized and applied to clinical departments. A retrospective study was conducted based on the established drug use evaluation criteria of Ketorolac Tromethamine， and analytic hierarchical model （AHM） method was used to evaluate the rationality of each 130 cases of Ketorolac Tromethamine before and after pre-prescription review in People's Hospital of Bozhou and 260 cases were randomly selected. Results The average medical record score before the pre-prescription review was 75.70±14.28， the average medical record score after the pre-prescription review was 87.48±11.45， it was statistically significant（P<0.05）. The per capita cost of Ketorolac Tromethamine was （250±414） yuan before the pre-prescription review，and the per capita cost of Ketorolac Tromethamine after the pre-prescription review was （128±148） yuan， and it was statistically significant（P<0.05）.The reasonable rate of indications，course of treatment， combination medication and curative effect had been improved after the pre-prescription review， the growth rate is more than 15%. Conclusion The customized rules of pre-prescription review based on drug use evaluation criteria can promote the rational use of Ketorolac Tromethamine and reduce the per capita cost of Ketorolac Tromethamine.
    • Medication in Primary Care
  • Recurrent ischemic stroke under the condition of regular secondary prevention: a case report
    XIONG Zhi-ping, ZHANG Ya-qing, MA Li, WU Ming-fen
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 65-68. https://doi.org/10.3969/j.issn.1672-3384.2021.11.013
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    • Pharmacy Adminstration
  • Essential drug changes between the 2021 and 2019 editions of World Health Organization Model List of Essential Medicines
    ZHAO Fei, ZHAO Zi-nan, JIN Peng-fei, LI Ke-xin, XUE Wei, QI Wen-yuan, WANG Juan, XU Xiao-yu, LIU Xiao-hui, YANG Lei, CONG Duan-duan, ZHANG Ya-tong, HU Xin
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 69-72. https://doi.org/10.3969/j.issn.1672-3384.2021.11.014
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective To study the update of 2021 edition of World Health Organization Model List of Essential Medicines （hereinafter referred to as "Model List"） published by World Health Organization on September 30， 2021， to provide reference for the selection of essential medicines in China. Methods We compared the 2021 edition of the Model List with the 2019 edition of the Model List， and analyzed the characteristics of the deleted and newly added drugs. Results The 2021 edition of the Model List had a total of 479 medicines， with 4 deletions and 24 new medicines compared to 459 in the 2019 edition. The 2021 edition of the Model List added a new major category of dental preparations， and incorporated more anti-infective and anti-tumor drugs. Drugs for precision therapy， fixed-dose combinations， more inhalation drugs and long-acting insulin analogues were included. Conclusion The inclusion of "new drugs" has been the trend of updating the Model List， and the new version of the Model List suggested that precision therapy drugs， combination therapy drugs and long-acting course drugs are one of the key directions for future drug development.
    • Medication Therapy Management
  • Nutritional therapy in severe malnutrition caused by anorexia nervosa: a case report of a child
    SHAN Jie-lin, SHANG Yong-guang
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 73-75. https://doi.org/10.3969/j.issn.1672-3384.2021.11.015
    Abstract ( ) Download PDF ( )   Knowledge map   Save
  • Stroke complicated with nonketotic hyperglycemia hyperosmolar coma: a case analysis of nutrition support therapy
    YE Fan, YU Di
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 76-79. https://doi.org/10.3969/j.issn.1672-3384.2021.11.016
    Abstract ( ) Download PDF ( )   Knowledge map   Save
  • Serious adverse reactions in patients with PD-1 inhibitors: two case reports and literature review
    YU Li-juan, LIU Yun, ZHONG Chao
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 80-83. https://doi.org/10.3969/j.issn.1672-3384.2021.11.017
    Abstract ( ) Download PDF ( )   Knowledge map   Save
  • Rickettsia felis complicated with Acinetobacter baumannii infection: a case report and drug use analysis
    YANG Xiao-shan, LI Hai-bin, YAN Zhi-dong, MO Qing-ming, LU Jun-lin, GUAN Jie-yan, FENG Chang-wen
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 84-86. https://doi.org/10.3969/j.issn.1672-3384.2021.11.018
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    • Case Report
  • Drug eruptions caused by Daptomycin: a case report
    WANG He, HU Lan
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 87-89. https://doi.org/10.3969/j.issn.1672-3384.2021.11.019
    Abstract ( ) Download PDF ( )   Knowledge map   Save
  • Grade 3 allergic reaction after repeated use of Rituximab: a case report
    LIANG Yong-li, YANG Hong-xin, TANG Kun
    CLINICAL MEDICATION JOURNAL. 2021, 19(11): 90-92. https://doi.org/10.3969/j.issn.1672-3384.2021.11.020
    Abstract ( ) Download PDF ( )   Knowledge map   Save
Copyright © Clinical Medication Journal, All Rights Reserved.
Tel: 010-64178704转301/302/305/306　
E-mail：zazhi@vip.sina.com
Powered by Beijing Magtech Co. Ltd.